Drug intelligence / Profile preview

RioMSK-001

Development stage: Unknown
Lead developer: RION
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intraarticular

Overview

RioMSK-001 is an investigational biologic drug comprising exosomes, currently under development for the treatment of osteoarthritis. It is administered via intraarticular injection and is based on Purified Exosome Product (PEP) technology. The drug aims to leverage the regenerative properties of exosomes to address musculoskeletal conditions, specifically targeting osteoarthritis. RioMSK-001 is being developed by Rion, a clinical-stage regenerative medicine company headquartered in Rochester, Minnesota[1][3][4].

Beyond the preview

Go deeper on RioMSK-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RioMSK-001.

Explore the full profile